Erratum to: Uso de recursos y costes asociados de episodios de hipoglucemia que requieren hospitalización en diabetes mellitus tipo 2 tratada con antidiabéticos orales en España (Estudio DYSCOVERY)

Abstract

© 2015, Springer International Publishing Switzerland.Objectives: To describe, in type 2 diabetes mellitus (DM2) patients on treatment with oral anti-diabetic drugs (OAD) hospitalized due to severe hypoglycemia, their clinical management and healthcare-related direct associated costs. Methods: Retrospective chart-review study (February 2010-November 2012). Adult (>18 years) DM2 patients treated with OAD monotherapy or combined OADs, hospitalized due to hypoglycemia were included. Variables: clinical and hospitalization data, OAD being used at the time of hypoglycemia and direct hospital stay-related costs. Results: In total 174 patients were included in 11 hospitals in Spain. Mean (SD) age 77.3 (9.6) years (>70 years: 80.5 %), 47.7 % male, 82.8 % urban residency, 8.6 % living alone, 98.9 % had co-morbidities, 37.4 % on OAD as monotherapy for 7.84 (6.15) years vs 10.99 (7.38) years for those on combined OADs. During the previous year 10.9 % suffered at least one hypoglycemic episode, 6.9 % hospitalized. Mortality 1.7 % and 11.04 % of patients were admitted to the ICU. Mean (SD) hospital stay 4.4 (5.0) days, mean (SD) cost 2246 (3421) €. Mean (SD) cost was 146 (137) € for diagnostic tests and 7.92 (7.6) € for pharmacological treatment. Conclusions: Severe hypoglycemic episodes requiring hospitalization in DM2 patients, predominantly elderly and with high number of co-morbidities, on treatment with OAD produce a high economic impact and are strongly related to the use of glibenclamide and low food intake. Most do not live alone and, caregivers’ education on DM care is potentially useful.